Virus Surveillance: Empowering Communities Through Early Genotypic Testing for HIV Drug Resistance
Experts now say that recent HIV epidemiology data and care gaps driven by the impact of the COVID-19 pandemic warrant increased vigilance to identify HIV drug resistance.
• Learn why testing for drug-resistant HIV mutations is timely.
• See recent policy decisions influencing HIV testing.
• Gain insights from virus surveillance, cluster detection and response efforts.
Health laboratories have an opportunity to position themselves at the forefront of reducing the harm of drug resistance and infectious disease. Exploring new options in viral genotyping HIV may be a promising path.
Produced in partnership with Thermo Fisher Scientific